- Home
- IDYA vs SPNT Comparison
IDYA vs SPNT Comparison
Compare IDYA & SPNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IDYA
- SPNT
- Stock Information
- Founded
- IDYA 2015
- SPNT 2011
- Country
- IDYA United States
- SPNT Bermuda
- Employees
- IDYA N/A
- SPNT N/A
- Industry
- IDYA Biotechnology: Pharmaceutical Preparations
- SPNT Property-Casualty Insurers
- Sector
- IDYA Health Care
- SPNT Finance
- Exchange
- IDYA Nasdaq
- SPNT Nasdaq
- Market Cap
- IDYA 2.2B
- SPNT 2.3B
- IPO Year
- IDYA 2019
- SPNT N/A
- Fundamental
- Price
- IDYA $22.18
- SPNT $14.99
- Analyst Decision
- IDYA Strong Buy
- SPNT
- Analyst Count
- IDYA 13
- SPNT 0
- Target Price
- IDYA $53.67
- SPNT N/A
- AVG Volume (30 Days)
- IDYA 890.0K
- SPNT 808.0K
- Earning Date
- IDYA 02-18-2025
- SPNT 02-18-2025
- Dividend Yield
- IDYA N/A
- SPNT N/A
- EPS Growth
- IDYA N/A
- SPNT 31.47
- EPS
- IDYA N/A
- SPNT 1.60
- Revenue
- IDYA $3,922,000.00
- SPNT $2,614,600,000.00
- Revenue This Year
- IDYA N/A
- SPNT N/A
- Revenue Next Year
- IDYA $251.89
- SPNT N/A
- P/E Ratio
- IDYA N/A
- SPNT $9.37
- Revenue Growth
- IDYA N/A
- SPNT N/A
- 52 Week Low
- IDYA $22.10
- SPNT $10.98
- 52 Week High
- IDYA $47.74
- SPNT $16.50
- Technical
- Relative Strength Index (RSI)
- IDYA 31.90
- SPNT 51.16
- Support Level
- IDYA $22.17
- SPNT $14.23
- Resistance Level
- IDYA $24.06
- SPNT $15.81
- Average True Range (ATR)
- IDYA 1.06
- SPNT 0.51
- MACD
- IDYA -0.22
- SPNT -0.01
- Stochastic Oscillator
- IDYA 1.84
- SPNT 40.78
About IDYA IDEAYA Biosciences Inc.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. It is engaged in applying capabilities across multiple classes of precision medicine, including direct targeting of oncogenic pathways and synthetic lethality. The company's product candidate IDE196 is a protein kinase C, or PKC, an inhibitor for genetically defined cancers having GNAQ or GNA11 gene mutations.
About SPNT SiriusPoint Ltd.
SiriusPoint Ltd provides property and casualty reinsurance coverage to insurance and reinsurance companies in the United States, Canada, Bermuda, the United Kingdom, and Europe. The company operates through two operating segments: Reinsurance and Insurance & Services. The company's product portfolio consists of reinsurance contracts for property insurance including both residential and commercial properties, workers' compensation, personal automobile, businesses' general liability insurance, professional liability insurance to protect professional advisors and service providers, agriculture insurance, and mortgage insurance. The majority of the revenue is generated from its Insurance & Services segment.